Document Detail


Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.
MedLine Citation:
PMID:  22733474     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent studies from our laboratory indicate that chlorthalidone triggers persistent activation of the sympathetic nervous system and promotes insulin resistance in hypertensive patients, independent of serum potassium. Mechanisms underlying these adverse effects of chlorthalidone remain unknown, but increasing evidence in rodents suggests the role of angiotensin and aldosterone excess in inducing both sympathetic overactivity and insulin resistance. Accordingly, we conducted studies in 17 subjects with untreated stage 1 hypertension, measuring sympathetic nerve activity at baseline and after 12 weeks of chlorthalidone alone (25 mg/d), chlorthalidone plus spironolactone, and chlorthalidone plus irbesartan, using randomized crossover design. We found that chlorthalidone alone decreased 24-hour ambulatory blood pressure from 135±3/84±2 to 124±2/78±2 mm Hg and significantly increased sympathetic nerve activity from baseline (from 41±3 versus 49±4 bursts per minute; P<0.01). The addition of spironolactone to chlorthalidone returned sympathetic nerve activity value to baseline (42±3 bursts per minute; P>0.05), whereas the addition of irbesartan failed to alter the sympathetic nerve activity response to chlorthalidone in the same subjects (52±2 bursts per minute; P<0.01) despite a similar reduction in ambulatory blood pressure (121±2/75±2 and 121±2/75±2 mm Hg, respectively). Chlorthalidone alone also increased indices of insulin resistance, which was not observed when used in combination with spironolactone. In conclusion, our study demonstrates beneficial effects of spironolactone in attenuating both chlorthalidone-induced sympathetic activation and insulin resistance in humans, independent of blood pressure reduction. Because sympathetic overactivity and insulin resistance contribute to the poor prognosis in patients with cardiovascular disease, combination therapy of chlorthalidone with mineralocorticoid receptor antagonists may constitute a preferable regimen than chlorthalidone alone in hypertensive patients.
Authors:
Prafull Raheja; Angela Price; Zhongyun Wang; Debbie Arbique; Beverley Adams-Huet; Richard J Auchus; Wanpen Vongpatanasin
Related Documents :
22227524 - Occurrence of hypotension in older participants. which 24-hour abpm parameter better co...
16662284 - Diffusion limitation of oxygen uptake and nitrogenase activity in the root nodules of p...
22121764 - Pressure-dependent dissipation effect at multiple cantilever resonant modes.
16621884 - Assessment of the relationship between cerebral and splanchnic oxygen saturations measu...
8793584 - Heart rate variability in hypertensive subjects.
16783414 - The role of urotensin ii in cardiovascular and renal physiology and diseases.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-06-25
Journal Detail:
Title:  Hypertension     Volume:  60     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-20     Completed Date:  2012-12-13     Revised Date:  2013-08-13    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  319-25     Citation Subset:  IM    
Affiliation:
Hypertension Section, Cardiology Division, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8586, USA.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00353652
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Action Potentials / drug effects,  physiology
Angiotensin II Type 1 Receptor Blockers / pharmacology
Biphenyl Compounds / pharmacology
Chlorthalidone / pharmacology*
Cross-Over Studies
Diuretics / pharmacology
Drug Therapy, Combination
Female
Heart Rate / drug effects,  physiology
Humans
Hypertension / classification,  physiopathology*
Insulin Resistance / physiology*
Male
Microelectrodes
Middle Aged
Spironolactone / pharmacology*
Sympathetic Nervous System / drug effects*,  physiology*
Tetrazoles / pharmacology
Treatment Outcome
Grant Support
ID/Acronym/Agency:
R01 HL078782/HL/NHLBI NIH HHS; R01HL-078782/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Biphenyl Compounds; 0/Diuretics; 0/Tetrazoles; 138402-11-6/irbesartan; 52-01-7/Spironolactone; 77-36-1/Chlorthalidone
Comments/Corrections
Comment In:
Hypertension. 2012 Dec;60(6):e42   [PMID:  23071128 ]
Hypertension. 2012 Aug;60(2):278-80   [PMID:  22733463 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Uteroplacental Insufficiency and Lactational Environment Separately Influence Arterial Stiffness and...
Next Document:  Blood Pressure and Obesity Exert Independent Influences on Pulse Wave Velocity in Youth.